VSee Health designates Series B Convertible Preferred Stock with $0.65 conversion price

VSEE HEALTH, INC.

Filed Certificate of Designation for 2,000 shares of Series B Preferred Stock, $1,000 stated value.
Dividends paid on as-converted-to-common basis only when common dividends paid.
Shares convertible into common at $0.65 per share, subject to 9.99% beneficial ownership cap.
Liquidation preference senior to common, pari passu with Series A Preferred Stock.
Conversion exercisable after investor gross proceeds from sale of all investor shares are less than $2.3M.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

VSEE HEALTH, INC.: On December 4, 2025, VSee Health, Inc. filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock with the Delaware Secretary of State, designating 2,000 shares of Series B Preferred Stock with a stated value of $1,000 per share, effective Decem (effective 2025-12-05).

Change: charter amendment
Effective: 2025-12-05

Exact text from the filing

On December 4, 2025, VSee Health, Inc. (the “Company”) filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “Series B Certificate of Designations”) with the Secretary of State of the State of Delaware, effective as of December 5, 2025, which provides for the designation of 2,000 shares of Series B Preferred Stock of the Company, par value $0.0001 per share (the “Series B Preferred Stock”), upon the terms and conditions as set forth in the Series B Certificate of Designations.

View on SEC.gov

276 governance changes filed in the last 30 days. Browse all governance changes →

VSEE HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001185185-25-002025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.